Lilly shows more positive Crohn's data for its IL-23 inhibitor as it continues to chase down rivals
About a year and a half after presenting positive topline results in Crohn’s disease, Eli Lilly gave its experimental IL …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
